The Association of Clinical Research Professionals

CAREER CENTER

Job Seekers, Welcome to ACRP Career Center
Search Filters
Use this area to filter your search results. Each filter option allows for multiple selections.
Search Results: 2356 Jobs
Save Agent
Loading... Please wait.
Usona

Madison, Wisconsin

Graphite Bio, Inc.

Brisbane, California

Frederick National Lab for Cancer Research Logo
Frederick National Lab for Cancer Research

Frederick, Maryland

Truveta, Inc.

Bellevue, Washington

Frederick National Lab for Cancer Research Logo
Frederick National Lab for Cancer Research

Bethesda, Maryland

Frederick National Lab for Cancer Research Logo
Frederick National Lab for Cancer Research

Frederick, Maryland

Meris Clinical Research

Brandon, Florida

FHI 360

Durham, North Carolina

Children's Health Dallas

Dallas, Texas

The University of Texas at Austin

Austin, Texas

Arkansas Children's Hospital

Little Rock, Arkansas

Maze Therapeutics Inc.

South San Francisco, California

Arcus Biosciences, Inc

Hayward, California

Virginia Commonwealth University

Richmond , Virginia

University of Illinois Cancer Center

Chicago, Illinois

Arkansas Children's

Little Rock, Arkansas

Arkansas Children's

Little Rock, Arkansas

Rush University Medical Center

Chicago, Illinois

OHSU Logo
OHSU

Portland, Oregon

OHSU Logo
OHSU

Portland, Oregon

OHSU Logo
OHSU

Portland, Oregon

CUNY Logo
CUNY

New York City, New York

Frontage Laboratories

Secaucus, New Jersey

Loading... Please wait.
Clinical Trial Associate
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, USA – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b


This job listing is no longer active.

Check the left side of the screen for similar opportunities.
Loading. Please wait.
Powered By Naylor Association Solutions